Krystal Biotech, Inc.
KRYS
$306.29
-$10.01-3.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 116.36M | 107.11M | 97.80M | 96.04M | 88.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 116.36M | 107.11M | 97.80M | 96.04M | 88.18M |
| Cost of Revenue | 6.32M | 6.59M | 4.26M | 7.17M | 5.03M |
| Gross Profit | 110.03M | 100.51M | 93.54M | 88.88M | 83.16M |
| SG&A Expenses | 41.01M | 41.45M | 37.58M | 35.16M | 32.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.67M | 62.84M | 56.43M | 56.74M | 51.93M |
| Operating Income | 53.69M | 44.27M | 41.37M | 39.31M | 36.25M |
| Income Before Tax | 61.44M | 51.13M | 47.97M | 46.78M | 43.60M |
| Income Tax Expenses | 5.51M | -269.00K | -31.40M | 8.44M | 7.86M |
| Earnings from Continuing Operations | 55.93M | 51.40M | 79.37M | 38.33M | 35.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.93M | 51.40M | 79.37M | 38.33M | 35.73M |
| EBIT | 53.69M | 44.27M | 41.37M | 39.31M | 36.25M |
| EBITDA | 54.21M | 44.83M | 41.68M | 39.62M | 36.66M |
| EPS Basic | 1.91 | 1.77 | 2.74 | 1.33 | 1.24 |
| Normalized Basic EPS | 1.31 | 1.10 | 1.04 | 1.01 | 0.95 |
| EPS Diluted | 1.83 | 1.70 | 2.66 | 1.29 | 1.20 |
| Normalized Diluted EPS | 1.26 | 1.06 | 1.00 | 0.98 | 0.91 |
| Average Basic Shares Outstanding | 29.29M | 29.09M | 28.95M | 28.91M | 28.82M |
| Average Diluted Shares Outstanding | 30.51M | 30.25M | 29.83M | 29.75M | 29.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |